Zelira Therapeutics Meets Primary Endpoints for Phase (1b/2a) Medicinal Cannabis Trial for Insomnia

Stock Information for Zelira Therapeutics Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Zelira Therapeutics Limited

Zelira Therapeutics Launches ZYRAYDI(TM) B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets
Zelira's Zenivol(TM), the World's First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany
Zelira(TM) Launches RAF FIVE(TM) Acne Treatment Products Through Its Dermatology Focused Subsidiary
Zelira Therapeutics Expands HOPE(TM) Distribution in the US Through Licensing Agreement with Alternative Solutions in Washington DC
Zelira Therapeutics Enters Agreement with Cardiovascular Solutions of Central Mississippi to Develop Products
Zelira Therapeutics Completes World's First Clinical Trials for Treatment of Insomnia with Medical Cannabis
Zelira Therapeutics To Collaborate With The Parkinson's Foundation
Zelira Therapeutics Expands HOPE® Distribution In The U.S.A

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.